Drug Price Trends for NDC 51672-4018

Average Pharmacy Cost for 51672-4018

Drug Name	NDC	Price/Unit ($)	Unit	Date
ETODOLAC 400 MG TABLET	51672-4018-01	0.25316	EACH	2026-03-18
ETODOLAC 400 MG TABLET	51672-4018-01	0.24626	EACH	2026-02-18
ETODOLAC 400 MG TABLET	51672-4018-01	0.25032	EACH	2026-01-21
ETODOLAC 400 MG TABLET	51672-4018-01	0.25142	EACH	2025-12-17
ETODOLAC 400 MG TABLET	51672-4018-01	0.26077	EACH	2025-11-19

Best Wholesale Price for NDC 51672-4018

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ETODOLAC 400MG TAB	Golden State Medical Supply, Inc.	51672-4018-01	100	15.75	0.15750	2023-06-15 - 2028-06-14	FSS

Novartis' Zolgensma (onasemnogene abeparvovec-xioi) Market Dynamics and Price Projections

Last updated: February 18, 2026

Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for spinal muscular atrophy (SMA), holds a significant position in the rare disease market due to its curative potential and high price point. This analysis examines its market penetration, competitive landscape, and projected pricing trajectory.

What is the Current Market Penetration of Zolgensma?

As of Q4 2023, Zolgensma has been administered to over 3,000 patients globally since its launch in 2019. The therapy is approved in over 50 countries, with key markets including the United States, Japan, and European Union member states. In the U.S., it received FDA approval in May 2019 for infants and children under two years of age with SMA. European Medicines Agency (EMA) approval followed in May 2019.

The primary indication is for the treatment of pediatric patients less than 24 months of age with homozygous mutations in the SMN1 gene. Clinical trials demonstrated significant efficacy, with treated patients showing improved motor function and survival rates compared to untreated individuals. For instance, the STR1VE clinical trial reported that 96% of pre-symptomatic infants treated with Zolgensma remained alive and free from permanent ventilation at 18 months of age, compared to historical data where the majority of untreated symptomatic SMA Type 1 infants required permanent ventilation by 2 years of age [1].

The limited patient population for SMA, estimated to affect approximately 1 in 10,000 live births, dictates the total addressable market size. While the incidence is low, the severity of the disease and the unmet medical need for a one-time curative treatment drive demand. Novartis has implemented patient access programs and financial assistance schemes to mitigate the economic burden on families and healthcare systems, acknowledging the therapy's substantial acquisition cost.

Who are Zolgensma's Key Competitors?

The competitive landscape for SMA treatments is evolving, primarily featuring a few gene therapies and ongoing pharmacological interventions.

• Spinraza (nusinersen): Developed by Biogen, Spinraza is an antisense oligonucleotide that has been the established treatment for SMA since its FDA approval in December 2016. It is administered via intrathecal injection, requiring lifelong treatment. Spinraza has a broad label, treating all types of SMA across all age groups. Its efficacy lies in increasing SMN protein levels.
• Evrysdi (risdiplam): Developed by Genentech (Roche), Evrysdi is an orally administered SMN2 splicing modifier approved in August 2020. It also works by increasing SMN protein levels and is indicated for patients 2 months of age and older. Evrysdi offers the convenience of oral administration and is approved for all SMA types.
• Research Pipeline: Several other gene therapies and novel treatment modalities are in various stages of clinical development. These include potential gene replacement therapies targeting different aspects of SMA pathology and other pharmacological agents. However, none have yet reached the market with the same curative claim and established reimbursement as Zolgensma.

The primary competitive differentiator for Zolgensma is its one-time administration and curative intent, positioning it as a definitive treatment option for eligible patients. Spinraza and Evrysdi offer chronic management solutions, with their total lifetime costs potentially rivaling or exceeding Zolgensma's upfront price, depending on patient adherence and disease progression.

What are the Projected Price Trajectory and Reimbursement Challenges?

Zolgensma is priced at approximately \$2.1 million per dose, making it one of the most expensive drugs globally. This pricing strategy reflects the value proposition of a one-time curative therapy for a devastating rare disease.

Pricing Strategy and Justification

Novartis' pricing for Zolgensma is based on a value-based assessment, considering the long-term cost savings to healthcare systems by averting lifelong care, hospitalizations, and intensive medical interventions associated with SMA. The company has engaged in extensive discussions with payers to establish reimbursement frameworks.

Reimbursement Landscape

Reimbursement for Zolgensma varies significantly by country and healthcare system.

• United States: In the U.S., Zolgensma is primarily reimbursed through private insurance and Medicaid. Novartis has established a program called "AveXis Patient Support" (now Novartis Gene Therapies Patient Support) to assist with insurance navigation, prior authorization, and financial assistance. The company has also introduced a payment plan option where payers can spread the cost over five years.
• European Union: Reimbursement in EU countries often involves complex negotiations with national health technology assessment (HTA) bodies and ministries of health. Value-based agreements and risk-sharing arrangements are common. For example, in Germany, an outcomes-based agreement was established.
• Other Markets: Reimbursement in other developed countries like Japan and Australia is also subject to local HTA processes and price negotiations. Developing markets may face greater access challenges due to economic constraints.

Price Projections

The price of Zolgensma is not expected to decrease significantly in the short to medium term. Given the high development costs associated with gene therapies and the unique value proposition of a one-time cure, Novartis is likely to maintain its current pricing strategy. Future price adjustments, if any, would likely be minor and tied to inflation or expanded indications.

The primary focus for price-related discussions will continue to revolve around the demonstration of long-term value and the development of sustainable reimbursement models. Payers are increasingly scrutinizing the long-term efficacy and cost-effectiveness of high-cost gene therapies. Novartis' continued investment in real-world evidence generation is crucial to support ongoing reimbursement negotiations and justify the therapy's price.

What are the Key Endpoints in Zolgensma Clinical Trials?

The clinical efficacy of Zolgensma is primarily assessed through key motor and survival endpoints, demonstrating its impact on disease progression and patient outcomes.

• Survival: The ability of patients to survive without permanent ventilation is a critical endpoint, especially for SMA Type 1. In the STR1VE trial, Zolgensma demonstrated a significant increase in event-free survival (defined as survival without permanent ventilation) compared to historical controls.
• Motor Milestone Achievement: Key motor milestones assessed include the ability to sit unaided, crawl, stand, and walk. Zolgensma treatment has shown that a significant proportion of treated infants achieve these milestones, which are typically not attained by individuals with severe SMA. For example, in the STR1VE trial, by 18 months of age, 70% of treated pre-symptomatic infants could sit without support, a milestone rarely achieved in untreated SMA Type 1.
• Swallowing and Feeding: The ability to swallow independently and maintain adequate oral nutrition is vital for SMA patients. Zolgensma has demonstrated improvements in these functions, reducing the need for feeding tubes.
• Respiratory Function: Assessments of respiratory muscle strength and function, often measured through parameters like forced vital capacity (FVC) and the need for mechanical ventilation, are also key indicators of treatment success.
• Motor Function Scales: Standardized motor function scales, such as the Hammersmith Functional Motor Scale-Expanded (HFMSE) and the Children's Hospital of Philadelphia (CHOP) Infant Test of Neuromuscular Disease (ITAND), are used to quantify motor improvements over time.

These endpoints have been instrumental in securing regulatory approvals and in Novartis' discussions with payers regarding the therapy's value proposition.

What is the Manufacturing and Supply Chain Complexity for Zolgensma?

The manufacturing and supply chain for Zolgensma present unique challenges inherent to gene therapy production.

Manufacturing Process

Zolgensma is a gene therapy that uses an adeno-associated virus (AAV9) vector to deliver a functional copy of the human survival motor neuron (SMN) gene. The process involves:

1. Vector Production: Large-scale cell culture to produce the AAV9 vector carrying the SMN gene. This requires highly specialized facilities and stringent quality control to ensure viral vector integrity and purity.
2. Purification: Complex multi-step purification processes to isolate the functional viral vectors from cellular debris and other impurities.
3. Formulation and Fill/Finish: The purified vector is formulated into a stable drug product and filled into vials under aseptic conditions.
4. Quality Control Testing: Extensive testing at various stages to ensure the safety, potency, and purity of the final product.

The manufacturing of viral vectors is a capital-intensive and technically demanding process, requiring specialized expertise and significant investment in infrastructure.

Supply Chain Management

The supply chain for Zolgensma is highly complex and global:

1. Cold Chain Logistics: Gene therapies are often sensitive to temperature fluctuations and require strict cold chain management from manufacturing to administration. This involves specialized packaging, transportation, and storage.
2. Global Distribution Network: Novartis has established a network of specialized treatment centers and distribution channels to ensure timely and safe delivery of Zolgensma to patients worldwide.
3. Just-in-Time Delivery: Given the limited shelf-life of some gene therapy products and the critical nature of patient treatment timing, efficient just-in-time delivery is essential.
4. Regulatory Compliance: Navigating diverse regulatory requirements for manufacturing, import/export, and distribution across different countries adds significant complexity.

The high cost of manufacturing and the intricacies of the supply chain contribute to the overall cost of Zolgensma and necessitate robust operational management. Any disruptions in this delicate process can have severe implications for patient access and treatment continuity.

What are the Post-Approval Studies and Real-World Evidence for Zolgensma?

Post-approval studies and the generation of real-world evidence (RWE) are critical for Zolgensma, particularly concerning long-term outcomes and payer negotiations.

Ongoing Clinical Trials and Registries

Novartis continues to conduct post-marketing studies to further assess the long-term safety and efficacy of Zolgensma. These include:

• Long-term follow-up studies: Extending the observation period of patients enrolled in original clinical trials to track durability of effect and identify any late-emerging safety signals.
• Patient registries: Maintaining and contributing to patient registries that collect data on Zolgensma-treated patients in routine clinical practice. These registries provide valuable RWE on a broader and more diverse patient population than typically enrolled in clinical trials.

Real-World Evidence Generation

RWE is crucial for demonstrating the value of Zolgensma to payers and healthcare providers. This evidence helps to:

• Confirm long-term benefits: Validate the sustained improvements in motor function, survival, and quality of life observed in clinical trials across a real-world patient cohort.
• Support economic value: Provide data to support the therapy's cost-effectiveness by demonstrating reductions in healthcare utilization (e.g., hospitalizations, ventilatory support, physical therapy) over time.
• Inform expanded indications: Contribute to the understanding of Zolgensma's potential benefits in broader patient populations or with different disease severities, which could lead to expanded indications.
• Address payer concerns: Provide robust data to address payer questions regarding long-term outcomes and the economic impact of the therapy.

The collection and analysis of RWE for gene therapies like Zolgensma are complex but essential for solidifying market access and demonstrating the transformative impact of these advanced treatments.

Key Takeaways

• Zolgensma (onasemnogene abeparvovec-xioi) has achieved global penetration with over 3,000 patients treated since its 2019 launch, supported by approvals in over 50 countries.
• Its competitive advantage lies in its one-time curative intent, differentiating it from chronic SMA treatments like Spinraza (nusinersen) and Evrysdi (risdiplam).
• The therapy is priced at approximately \$2.1 million per dose, with reimbursement varying by region and often involving value-based agreements and payment plans.
• Key clinical trial endpoints focus on survival without permanent ventilation and achievement of motor milestones, demonstrating significant efficacy.
• Manufacturing and supply chain for Zolgensma are complex, requiring specialized infrastructure and stringent cold chain logistics, contributing to its high cost.
• Ongoing post-approval studies and real-world evidence generation are critical for validating long-term benefits and supporting ongoing payer negotiations.

FAQs

1. What is the estimated total addressable market size for Zolgensma? The total addressable market is constrained by the incidence of SMA, estimated at approximately 1 in 10,000 live births. The specific number of eligible patients requiring Zolgensma is further defined by age and genetic profile (homozygous mutations in SMN1), with an estimated annual incidence of new diagnoses in the low thousands globally.

2. How does Zolgensma's price compare to the lifetime cost of alternative SMA treatments? While Zolgensma has a high upfront cost, its one-time administration aims to avert the cumulative costs associated with lifelong treatments like Spinraza and Evrysdi, which involve ongoing drug acquisition, administration, and associated healthcare utilization over many years. Comparative economic models are used to justify Zolgensma's value proposition.

3. What are the primary hurdles in obtaining reimbursement for Zolgensma in different countries? Key hurdles include demonstrating long-term cost-effectiveness to national health technology assessment (HTA) bodies, negotiating fair pricing that reflects the therapy's curative value, and establishing sustainable payment models that accommodate the significant upfront cost within healthcare budgets.

4. Are there any ongoing efforts to reduce the manufacturing cost of Zolgensma? While specific cost reduction initiatives are proprietary to Novartis, the gene therapy sector generally sees ongoing investment in optimizing manufacturing processes, improving vector yield, and enhancing purification efficiency to reduce the cost of goods over time.

5. What role does real-world evidence play in Zolgensma's market access strategy? Real-world evidence is crucial for validating the long-term durability of Zolgensma's effects, demonstrating its impact on reducing healthcare resource utilization, and providing data to support ongoing discussions with payers to ensure continued market access and patient eligibility for treatment.

Citations

[1] Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Swanson, E., ... & Kaspar, B. K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine, 377(18), 1713-1722.